Relationship between severity of adult community-acquired pneumonia and impairment of the antioxidant defense system

• Rodrigo L Castillo ^[1] ; Rodrigo A Carrasco ^[2] ; Pedro I Álvarez ^[3] ; Mauricio Ruiz ^[4] ; Vivian Luchsinger ^[5] ; Enna Zunino ^[6] ; María A Martínez ^[5] ; Luis F Avendaño ^[5]
  1. [1] University of Chile Faculty of Medicine Pathophysiology Program
  2. [2] Salvador Hospital Medicine Department
  3. [3] Medicine Department Faculty of Medicine Institute of Biomedical Sciences
  4. [4] University of Chile Clinical Hospital Medicine Department
  5. [5] University of Chile Faculty of Medicine Virology Program
  6. [6] Infectious Disease Hospital Dr. Lucio Córdova

  Mostrar afiliaciones +
• Localización: Biological Research, ISSN-e 0717-6287, ISSN 0716-9760, Vol. 46, Nº. 2, 2013, págs. 207-213
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Oxidant/antioxidant imbalance has been reported in some infectious diseases, including community-acquired pneumonia (CAP). The aim was to assess the antioxidant status in adults with CAP and its relationship with clinical severity at admission. Fifty-nine patients with CAP were enrolled and categorized at admission by the FINE score, from July 2010 to October 2012. In the same period 61 controls were enrolled. Plasma samples were obtained at admission for determination of the ferric reducing ability of plasma (FRAP) and lipid peroxidation (8-isoprostane). Erythrocyte reduced (GSH)/oxidized (GSSG) glutathione, malondialdehyde (MDA) and antioxidant enzyme activity were assessed. Antioxidant status in adults with CAP represented by FRAP and the GSH/GSSG ratio were 16.8% (p=0.03) and 39.7% (p=0.04) lower than control values, respectively. In addition, FRAP values showed a positive correlation with GSH/GSSG ratio (r=0.852; p<0.02; n=59). The CAP group showed greater lipid peroxidation in both plasma and erythrocytes. The FINE score correlated negatively with FRAP (r= -0.718; p<0.05; n=59) and positively with MDA and F2 isoprostane levels (r=0.673; p<0.05; n=59; r=0.892; p<0.01; n=59, respectively). Antioxidant status alterations correlated with clinical severity. The FRAP assay and lipid peroxidation biomarkers may provide a useful parameter for estimating the severity and the clinical outcome of patients with CAP.